BUTISOL SODIUM® (butabarbital sodium tablets, USP and butabarbital sodium oral Remedy, USP) may be the sodium salt of the weak acid. Barbiturates are weak acids which can be absorbed and rapidly distributed to all tissues and fluids with high concentrations in the Mind, liver, and kidneys.
Tricyclic Antidepressants: Barbiturates may boost the metabolism of Tricyclic Antidepressants. Management: Check for diminished efficacy of tricyclic antidepressants if a barbiturate is initiated/dose greater, or greater consequences if a barbiturate is discontinued/dose lowered. Tricyclic antidepressant dose adjustments are possible required. Look at therapy modification
Servicing of the ample airway, with assisted respiration and oxygen administration as vital.
butabarbital will lessen the level or outcome of flurbiprofen by impacting hepatic enzyme CYP2C9/ten metabolism. Small/Significance Unknown.
butabarbital will decrease the extent or impact of vinblastine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Not known.
buprenorphine subdermal implant and butabarbital each enhance sedation. Keep away from or Use Alternate Drug. Limit use to clients for whom alternative cure solutions are insufficient
Anticoagulant dose decreases might be essential pursuing barbiturate discontinuation or dose reduction. Take into consideration therapy modification
butabarbital will lower the level or result of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
butabarbital will minimize the level or influence of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
butabarbital will decrease the level or influence of vinorelbine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Not known.
Hypersensitivity to barbiturates or any component on the formulation; ; background of manifest or latent porphyria
Barbiturates usually do not impair normal hepatic purpose, but are already demonstrated to induce liver microsomal enzymes, thus escalating and/or altering the metabolism of barbiturates as well as other prescription drugs (see Safety measures-DRUG INTERACTIONS).
butabarbital and olopatadine intranasal both maximize click here sedation. Stay away from or Use Alternate Drug. Coadministration improves risk of CNS melancholy, which may result in additive impairment of psychomotor effectiveness and bring about daytime impairment.
butabarbital will lessen the level or effect of etravirine by impacting hepatic enzyme CYP2C9/ten metabolism. Use Warning/Watch.